Preprint: vaccine breakthrough coronavirus infections may be common in transplant patients

Coronavirus, Health, Infection, Moderna, PCR, Pfizer/Biontech, Science, Testing, Vaccine, Vaccine Breakthrough

“We studied 658 transplant recipients who received 2 doses of SARS-CoV-2 mRNA vaccine. At a median of 21 days after dose 1, antibody was detectable in 98 participants (15%). At a median of 29 days after dose 2, antibody was detectable in 357 participants (54%).  Overall, of the 658 participants, 98 (15%) had measurable antibody response after dose 1 and dose 2; 301 (46%) had no antibody response after dose 1 or dose 2; and 259 (39%) had no antibody response after dose 1 but subsequent antibody response after dose 2.” preprint: “Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients”


Finland: 80% vaccine breakthrough in hospital with B16172 Delta coronavirus variant – PPE no longer effective – UPDATED

** This post was originally published on June 10, 2021 **